3 May 2023

At the meeting of 4 April 2023 the RMA:

Determined Statements of Principles (SOPs) for:

Condition SOPs
decompression illness 23/2023 24/2023
shingles and postherpetic neuralgia 27/2023 28/2023
chickenpox 29/2023 30/2023
albinism 31/2023 32/2023
alpha-1 antitrypsin deficiency 33/2023 34/2023
autosomal dominant polycystic kidney disease 35/2023 36/2023
Gaucher disease 37/2023 38/2023
haemophilia 39/2023 40/2023
hereditary spherocytosis 41/2023 42/2023
multiple osteochondromatosis 43/2023 44/2023
von Willebrand disease 45/2023 46/2023
Wilson disease 47/2023 48/2023
Huntington disease 49/2023 50/2023
Marfan syndrome 51/2023 52/2023
osteogenesis imperfecta 53/2023 54/2023
melioidosis 55/2023 56/2023
chronic myeloid leukaemia 57/2023 58/2023

These SOPs revoke the SOPs previously determined for these conditions.

Determined New Statements of Principles (SOPs) for:

Condition SOPs
plantar fibromatosis 21/2023 22/2023
retinal burn 25/2023 26/2023

Determined Amendment Statements of Principles (SOPs) for:

Condition SOPs
external burn 59/2023 60/2023

The above SOPs take effect from 23 May 2023.

Completed Investigations

The above determinations conclude the previously advertised investigations into:

New Investigation

Decided to advertise the following investigation:

The above investigation notice appears in the Government Notices Gazette of 28 April 2023.